Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

New research shows that Amgen’s Repatha, part of a new class of treatments that dramatically lower cholesterol known as PCSK9 inhibitors, decreased the amount of plaque in patients with heart ...

A pair of cholesterol-lowering drugs approved within one month of each other will both be covered by Express Scripts at a time when payers have become much more stringent about which therapies they ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...